Biotechnology - Kit Writing Sample

Background

To develop a cohesive kit insert for Glycogen (5 mg/ml), used with DNA/RNA extraction applications.

Audience

- Biotechnology scientists, lab technicians, and researchers.

Scope

Reagent name, catalog number, description, usage, quality control, warranty, and disclaimers.

About biotechnology - kit writing sample

The following writing sample contains the information included in the product packaging as an insert.

Note: To prevent proprietary issues, I have removed the original formatting and changed the company name, document name, product names, licenses, trademarks, components (including third-party components), applications, guides, codes, and sample codes where applicable.

Document title:
Glycogen (5 mg/ml)

Catalog Number:
AM9510

Pub. No.:
4386634 Rev. A

Contents	Quantity	Storage conditions
Glycogen (5 mg/ml)	5 x 1 mL	Store at -20°C. Do not store in a frost-free freezer.

WARNING! Read the Safety Data Sheets (SDSs) and follow the handling instructions. Wear appropriate protective eyewear, clothing, and gloves. Safety Data Sheets (SDSs) are available from www.lifetechnologies.com/support.

Product description

Glycogen is a branched chain carbohydrate intended for use as a carrier for nucleic acid precipitation. This product is treated with Proteinase K and SDS to remove any contaminating nucleases, then extracted with phenol/chloroform, ethanol precipitated and resuspended in nuclease-free water.

Note: Glycogen is isolated from a biological source (mussels). Therefore, preparations may contain minute concentrations of DNA that may be detectable by RT-PCR and PCR.

Source: Mussel

Storage buffer (not included): Nuclease-free Water

Using Glycogen

Glycogen offers a means of enhancing precipitation without adding appreciable amounts of exogenous nucleic acids to the sample. For this reason, it is preferable to yeast RNA as a coprecipitant for applications where added nucleic acid could interfere or compete with subsequent enzymatic reactions. For example, glycogen may be an appropriate coprecipitant when using terminal transferase to add non-template directed nucleotides to the 3' ends of DNA fragments or when using polynucleotide kinase to end-label oligonucleotides.

For precipitation of nucleic acids:
1. Adjust the monovalent cation concentration of the solution (for example to 0.5 M Ammonium Acetate).
2. Add glycogen to a final concentration of 10–150 µg/mL, mix well, and then mix with one volume of isopropanol or two volumes of ethanol.
3. Chill the mixture for at least 15 minutes at –20°C or below, then centrifuge for at least 15 min at ≥10,000 x g.
4. Carefully remove the supernatant fluid and resuspend the nucleic acid in the desired buffer.

Quality control

Nonspecific endonuclease activity: A sample is incubated with supercoiled plasmid DNA and analyzed by agarose gel electrophoresis.

Exonuclease activity: A sample is incubated with labeled double-stranded DNA, followed by PAGE analysis.

RNase activity: A sample is incubated with labeled RNA and analyzed by PAGE.

Limited product warranty

[Biotechnology Company] and/or its affiliate(s) warrant their products as set forth in the [Biotechnology Company] *General Terms and Conditions of Sale* found on [Biotechnology Company] website at www.[Biotechnology Company].com/termsandconditions.

If you have any questions, contact [Biotechnology Company] at www.[Biotechnology Company].com/support.

For Research Use Only. Not for use in diagnostic procedures.

The information in this guide is subject to change without notice.

DISCLAIMER: LIFE TECHNOLOGIES CORPORATION AND/OR ITS AFFILIATE(S) DISCLAIM ALL WARRANTIES WITH RESPECT TO THIS DOCUMENT, EXPRESSED OR IMPLIED, INCLUDING BUT NOT LIMITED TO THOSE OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR NON-INFRINGEMENT. TO THE EXTENT ALLOWED BY LAW, IN NO EVENT SHALL LIFE TECHNOLOGIES AND/OR ITS AFFILIATE(S) BE LIABLE, WHETHER IN CONTRACT, TORT, WARRANTY, OR UNDER ANY STATUTE OR ON ANY OTHER BASIS FOR SPECIAL, INCIDENTAL, INDIRECT, PUNITIVE, MULTIPLE OR CONSEQUENTIAL DAMAGES IN CONNECTION WITH OR ARISING FROM THIS DOCUMENT, INCLUDING BUT NOT LIMITED TO THE USE THEREOF.

For support www.[Biotechnology Company].com/support. or email techsupport@[Biotechnology Company].com.

28 January 2013